Xenetic Biosciences Acquires Santersus to Expand Therapeutic Platform
Xenetic Biosciences Inc (NASDAQ: XBIO) has entered into a definitive share exchange agreement to acquire privately held Santersus AG, enhancing its therapeutic platform focused on selective blood purification. The all-stock deal requires shareholder approval and will result in the combined entity rebranding as Santersus Bio, Inc., trading under the ticker symbol 'SNTS' on Nasdaq. The acquisition aims to create a multi-indication clinical-stage company targeting neutrophil extracellular traps (NETs), which are linked to various diseases including oncology and autoimmune disorders. The new entity will combine NucleoCapture technology from Santersus, designed to filter NETs physically, with Xenetic's DNase platform that breaks down NETs enzymatically. Xenetic Biosciences' stock was trading at $2.52 as of the article’s publication date, reflecting a 40.98% decline in share price.
Tickers: $XBIO
Topics: Biotech Clinical Trials Medical Devices NETs (Neutrophil Extracellular Traps)